FDA Rejects Nastech's Application

Shares of Nastech Pharmaceutical Co. (NSTK) fell $2.40 to close at $12.86 after the Food and Drug Administration rejected the company's application to develop a generic version of Novartis AG's (NVS) Miacalcin nasal spray. Novartis stock eased 46 cents to close at $55.16.